Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyCarolina Behavioral NAS Coverage | OpenPayer
    Ask Trek AI about this page
    ModifiedCarolina Behavioral Health AlliancePolicy CP.MP.86

    Neonatal Abstinence Syndrome Guidelines

    Customize your policy alerts

    Sign up for carolinabehavioralhealth Policy CP.MP.86 alerts

    Get alerted when Policy CP.MP.86 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs medically necessary observation, assessment, treatment, level of care, and discharge planning for infants exposed in utero to opioids or other substances and at risk for neonatal abstinence syndrome (NAS). It applies to providers managing asymptomatic or symptomatic neonates, including infants receiving nonpharmacologic, pharmacologic, or home-based withdrawal care.

    Policy Summary
    PayerCarolina Behavioral Health Alliance
    PolicyNeonatal Abstinence Syndrome Guidelines
    Policy CodePolicy CP.MP.86
    Change TypeMaterial revision
    Effective DateN/A
    Next Review DateN/A
    Key ActionSchedule a primary-care pediatrician or family medicine follow-up appointment before discharge.
    SourceLink
    POLICY UPDATE CHANGES

    The revised criteria removed use of the modified Finnegan Neonatal Abstinence Scoring Tool from criterion I.A.1.

    Criterion I.A.2 removed the requirement to use the Eat, Sleep, Console approach and added treatment-duration language.

    Language concerning placement in a level II nursery was removed from criterion I.B.

    Criterion I.C.2 was revised to require no significant clinical signs of withdrawal for 24 to 48 hours after applicable pharmacologic therapy before discharge.

    Criterion I.C.4 was revised to require parent or caregiver education regarding NAS and routine infant care, with demonstrated understanding and agreement with the plan of care.

    Criterion I.C.8 added a requirement that a follow-up appointment with the primary care pediatrician or family medicine provider be scheduled before discharge.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    55%-94%
    Neonates exposed in utero who develop withdrawal signs
    4-7 daysObservation duration for at-risk asymptomatic infants
    48 hoursRecommended follow-up after discharge
    3 scores >8Modified Finnegan pharmacologic threshold
    10 minutesESC consolability threshold
    24-48 hoursWithdrawal-free period before discharge after therapy

    Medical Necessity and Coverage Criteria

    Home-Based Withdrawal Therapy for Opioid-Exposed Infants

    Home-based withdrawal therapy for an opioid-exposed infant may be considered only when ALL of the following are met:

    ALL of the following

    • The infant is opioid-exposed and is being considered for home-based withdrawal therapy.
    • During the prior 48 hours, the infant has had no more than two modified Finnegan scores of 8 or higher and no modified Finnegan score greater than 10.
    • All discharge-to-home-with-home-health criteria in the Discharge Criteria group are met.
    • The supports available in the home environment and the abilities and needs of the caregivers have been assessed and considered.
    • For an infant treated pharmacologically using ESC, discharge is consistent with ESC recommendations.

    Discharge Home With Home Health

    Before discharge home with home health, ALL of the following requirements must be met:

    ALL of the following

    • Clinical stability

      • The infant is taking oral feeds and gaining weight satisfactorily.
      • The infant is physiologically stable, with normal vital signs, including blood pressure.
    • The infant demonstrates neurobehavioral recovery, including reaching a full alert state, responding to social stimuli, and being consoled with appropriate measures, with no significant clinical signs of withdrawal for 24 to 48 hours after applicable pharmacologic therapy.
    • The home situation has been assessed and deemed adequate.

    Pharmacologic Selection, Weaning, and Monitoring

    When pharmacologic treatment is medically necessary, selection, dosing, tapering, and monitoring follow ALL of the following principles:

    ALL of the following

    • Medication selection

      • For an opioid-exposed infant when nonpharmacologic treatment fails, the first-line medication is an opioid such as morphine, methadone, or buprenorphine.
      • Clonidine and phenobarbital are second-line medications used in addition to an opioid to treat NAS when needed.
      • Paregoric and diazepam are not recommended.
      • Once opioid medication is started under ESC, it does not need to be continued or increased unless the infant fails to eat, sleep, or be consoled.
    • Response-based dosing and weaning

    Nursery days are not medically necessary when an infant is clinically stable but remains hospitalized solely because of social issues, unless the applicable benefit provides coverage for those days.

    Continued nursery care is not medically necessary for a clinically stable infant when hospitalization is solely for social reasons, subject to any benefit coverage that specifically requires or covers such days.

    Clinical Thresholds and Monitoring Parameters

    ESC feeding threshold
    Breastfeeding or bottle-feedingBreastfeed/chestfeed well or take greater than 1 ounce (30 mL) per feed
    Assessment domainEat
    ESC implicationIf the infant cannot meet the feeding standard despite intensive comfort care, pharmacologic treatment may be considered for opioid withdrawal
    ESC sleep threshold
    Undisturbed sleepGreater than or equal to 1 hour
    Assessment domainSleep
    ESC implication

    Documentation, Assessment, and Discharge Actions

    Documentation Required

    Document All Home Discharge Criteria

    Before discharge home with home health, document that the infant meets every applicable clinical, neurologic, home-support, and follow-up requirement.

    • Infant is clinically stable, taking oral feeds, gaining weight satisfactorily, and has normal vital signs, including blood pressure.
    • Document neurobehavioral recovery: full alert state, response to social stimuli, ability to be consoled with appropriate measures, and no significant clinical signs of withdrawal for 24–48 hours after applicable pharmacologic therapy.
    • Assess and document an adequate home situation, available transportation for follow-up, arranged home nursing assessments, and confirmation of the responsible physician and backup healthcare facility with the family and home-care agency.
    • Schedule follow-up with the primary care pediatrician or family medicine provider before discharge; an opioid-exposed infant should generally be seen within 48 hours after discharge to monitor for withdrawal.
    Documentation Required

    Verify Home-Withdrawal Eligibility

    Clinical Background

    Neonatal abstinence syndrome (NAS) is neonatal withdrawal resulting from in-utero exposure to opioids and/or other substances, including central nervous system depressants, antidepressants, cocaine, and other central nervous system stimulants. Neonatal opioid withdrawal syndrome refers specifically to withdrawal caused by opioid exposure alone, while symptoms after selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor exposure are generally described as neonatal adaptation syndrome. The onset and severity of symptoms vary according to the substance involved, its half-life, the timing of the last exposure, and polysubstance exposure; therefore, universal screening and risk-based observation are important.

    Definitions and Assessment Approaches

    Neonatal opioid withdrawal syndrome (NOWS)
    DefinitionNeonatal opioid withdrawal symptoms caused by in-utero opioid exposure alone
    Exposure typeOpioid exposure only
    Relationship to NASNOWS is distinct from NAS, which includes opioid and nonopioid exposures
    Neonatal abstinence syndrome (NAS)
    DefinitionNeonatal withdrawal resulting from in-utero exposure to opioids and/or nonopioid substances
    Policy usageThe policy uses NAS for opioid and other substance exposures
    Included exposures
    Policy Summary
    PayerCarolina Behavioral Health Alliance
    PolicyNeonatal Abstinence Syndrome Guidelines
    Policy CodePolicy CP.MP.86
    Change TypeMaterial revision
    Effective DateN/A
    Next Review DateN/A
    Key ActionSchedule a primary-care pediatrician or family medicine follow-up appointment before discharge.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaClinical Thresholds and Monitoring ParametersDocumentation, Assessment, and Discharge ActionsClinical BackgroundDefinitions and Assessment Approaches
    The parent(s) or caregiver(s) have received education regarding NAS and routine infant care, demonstrate understanding of the plan of care, and agree with the plan.
  1. Appropriate transportation is available for follow-up appointments.
  2. Home care services are arranged for nursing assessments.
  3. The responsible physician—neonatologist, primary care pediatrician, or family medicine provider—and a backup health care facility, such as a NICU or community hospital, are confirmed with the family and home care agency before discharge.
  4. A follow-up appointment with the primary care pediatrician or family medicine provider is scheduled before discharge.
  5. For an opioid-exposed infant, follow-up with the provider is arranged within 48 hours after discharge to monitor for withdrawal signs.
    • The course of opioid therapy is determined by the infant's clinical response and abstinence scores; an increased dose may be indicated if the infant remains symptomatic.
    • After the infant responds, abstinence scores decrease, and weight gain is established, medication weaning may begin, taking metabolic demands and overall clinical status into account.
    • Morphine may be weaned every 24 to 48 hours for a single-drug regimen and no more frequently than every 48 hours for a multiple-drug regimen or after a recently failed wean.
    • Morphine may be discontinued after reaching 0.02 mg/kg/dose every three to four hours, and the dosing interval should not be extended beyond every three to four hours to avoid subtherapeutic levels before the next dose.
    • Clonidine may be weaned every 24 hours by 0.25 to 0.5 mcg/kg/dose as tolerated; blood pressure and vital signs must be monitored every two hours for 12 hours after clonidine is completely weaned to detect rebound hypertension or tachycardia.
    • Phenobarbital may be weaned every 48 hours by decreasing the dose by 20%; alternatively, the infant may be discharged on phenobarbital and allowed to outgrow the dose over two to three weeks before discontinuation.
  6. Monitoring and clinical judgment

    • Morphine half-life is variable and inversely related to gestational age; clearance increases as gestational age and birth weight increase.
    • For opioid-exposed infants, morphine dosing should occur no less frequently than every four hours to avoid subtherapeutic levels before the next dose.
    • Clinical judgment is essential throughout pharmacologic management, including dose adjustment, weaning, and discontinuation.
  7. If the infant cannot sleep to this standard despite intensive comfort care, pharmacologic treatment may be considered for opioid withdrawal
    ESC consolability threshold
    ConsolabilityBe consoled within 10 minutes
    Assessment domainConsole
    ESC implicationIf the infant cannot be consoled within this time despite intensive comfort care, pharmacologic treatment may be considered for opioid withdrawal
    Modified Finnegan pharmacologic initiation
    Consecutive-score criterionGenerally three or more consecutive modified Finnegan scores above 8
    Average-score criterionAlternatively, two consecutive scores averaging 12 or greater
    Required conditionCriteria apply despite adequate supportive care
    Home opioid withdrawal eligibility
    Scores of 8 or greaterNo more than two modified Finnegan scores greater than or equal to 8 during the prior 48 hours
    Score above 10No more than one score greater than 10 during the prior 48 hours
    Additional requirementAll applicable discharge criteria must also be met, with home supports and caregiver abilities considered
    Morphine discontinuation
    Discontinuation dose0.02 mg/kg/dose
    Dosing intervalEvery 3 to 4 hours
    Safety limitationMorphine should not be spaced beyond every 3 to 4 hours before the next dose
    Clonidine monitoring after weaning
    Blood-pressure monitoringMonitor blood pressure every 2 hours
    Vital-sign monitoringMonitor vital signs every 2 hours
    Monitoring durationFor 12 hours after clonidine is completely weaned

    Home-based withdrawal therapy for an opioid-exposed infant may be considered only when recent modified Finnegan results and all home-discharge requirements support safe treatment outside the hospital.

    • In the prior 48 hours, there must be no more than two modified Finnegan scores of ≥ 8 and no score > 10.
    • All discharge criteria in section I.C. must be met, including clinical stability, neurobehavioral recovery, adequate home support, caregiver readiness, home nursing, responsible-provider confirmation, and scheduled follow-up.
    • Consider the supports available in the home and the abilities and needs of the caregivers. If pharmacologic therapy was administered using ESC, discharge should be consistent with ESC recommendations.
    Documentation Required

    Document NAS Assessment and Differential Diagnosis

    Document the clinical basis for the NAS diagnosis and the evaluation that distinguishes withdrawal from other causes of neonatal symptoms.

    • Record the birthing individual’s prescription and substance-use history, including known or suspected illicit substance use, disclosed recent use, high-risk behaviors, intoxication, and relevant obstetric or medical findings.
    • Use appropriate maternal toxicology testing when indicated and document newborn urine, meconium, and/or umbilical-cord testing when performed, including limitations such as false negatives and the need to confirm false positives before reporting where required.
    • Document neonatal observation and assessment findings. Clinical diagnosis is based on the maternal substance/medication history together with neonatal screening, observation, and assessment results.
    • Evaluate withdrawal-like findings—including seizures, fever, irritability, and poor feeding—with appropriate assessment and diagnostic testing to differentiate NAS from other diagnoses.
    Documentation Required

    Confirm Caregiver Education and Agreement

    Before discharge, ensure caregivers are prepared to manage NAS and routine infant care and explicitly agree with the plan of care.

    • Provide education regarding NAS and routine infant care.
    • Document that each parent or caregiver demonstrates understanding of the education and agrees with the plan of care.
    • Coordinate caregiver understanding with the home-care plan, follow-up arrangements, and instructions for monitoring after discharge.
    Denial Risk

    Social-Only Nursery Days Are Not Medically Necessary

    A clinically stable infant who remains in the nursery solely because of social issues does not meet medical necessity for additional nursery days unless a benefit specifically provides coverage for those days.

    • Do not support continued hospitalization as medically necessary when the infant is clinically stable and the only remaining reason for the stay is a social issue.
    • Document any ongoing medical indication separately from social barriers.
    Documentation Required

    Use the Decision-Driving Assessment Tool

    Use the assessment system that actually directs treatment and level-of-care decisions when documenting medical necessity; do not rely on a secondary scoring system used only for comparison.

    • The hospital may use either the modified Finnegan Neonatal Abstinence Scoring Tool (FNAST) or the Eat, Sleep, Console (ESC) approach.
    • If both FNAST and ESC are recorded, only the system used to direct care decisions should inform medical-necessity determinations.
    • Document the selected tool, the resulting assessments, and how those results directed observation, treatment, transfer, or discharge decisions.
    Opioids, central nervous system depressants, SSRIs/SNRIs, and other substances may produce neonatal symptoms or withdrawal
    Neonatal adaptation syndrome
    DefinitionSymptoms in neonates exposed to selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors
    Typical onsetSeveral hours to several days after birth
    Typical courseSymptoms generally subside within one to two weeks
    Eat, Sleep, Console (ESC)
    Functional assessmentEvaluates whether the infant can eat or breastfeed/chestfeed adequately, sleep undisturbed, and be consoled within the specified time
    Feeding standardBreastfeed/chestfeed well or take greater than 1 ounce (30 mL) per feed
    Other functional standardsSleep undisturbed for at least 1 hour and be consoled within 10 minutes
    Modified Finnegan Neonatal Abstinence Scoring Tool (FNAST)
    DefinitionA neonatal withdrawal scoring method used to assess symptoms and guide care decisions for infants at risk for NAS
    Use in policyMay be used to assess and manage infants together with the ESC approach
    Level-of-care applicationUnder modified FNAST, Level II care is appropriate when medications are given and/or the infant is transferred to the NICU
    Eat, Sleep, Console (ESC) assessment approach
    Assessment focusEvaluates the infant's ability to eat, sleep, and be consoled
    Treatment componentsIncludes nonpharmacologic and pharmacologic treatment
    Care modelEmphasizes infant function and comfort and promotes maternal or caregiver involvement
    Finnegan Neonatal Abstinence Scoring Tool (FNAST)
    DefinitionA widely adopted scoring system and modified versions designed primarily for use in term infants to assess neonatal abstinence signs
    Assessment purposeAssesses signs and symptoms of neonatal abstinence
    Policy contextThe policy permits use of modified FNAST or the ESC approach
    Cocaine and CNS-stimulant exposure
    DefinitionNeurobehavioral symptoms after intrauterine exposure to cocaine or other central nervous system stimulants
    Common symptomsIrritability, hyperactivity, tremors, high-pitched cry, and excessive sucking
    Clinical interpretationSymptoms may reflect direct drug effects rather than withdrawal because cocaine and metabolites can remain detectable in neonatal urine for up to three days after birth
    Poor neonatal adaptation
    DefinitionA group of symptoms after third-trimester SSRI/SNRI exposure
    SymptomsMay include continuous crying, irritability, jitteriness, restlessness, shivering, fever, tremors, respiratory distress, feeding difficulty, sleep disturbance, hypoglycemia, and seizures
    Clinical terminologyDescribed as poor neonatal adaptation because it is unclear whether symptoms represent serotonin syndrome or SSRI withdrawal